Literature DB >> 23666388

Health-related quality of life in patients with brain tumors: limitations and additional outcome measures.

Linda Dirven1, Jacob C Reijneveld, Neil K Aaronson, Andrew Bottomley, Bernard M J Uitdehaag, Martin J B Taphoorn.   

Abstract

Health-related quality of life (HRQOL) is a multidimensional concept used to measure patients' functioning and well-being. In recent decades, HRQOL has become an important (secondary) outcome measure in clinical trials for brain tumor patients. It could be questioned, however, whether HRQOL is the only useful outcome measure for assessing the level of functioning and well-being of these patients. As described in this review, several general methodological issues can hamper the interpretation of HRQOL data collected in the oncology setting. Additionally, because brain tumor patients have a progressive brain disease resulting in cognitive impairments, patient-reported outcomes may not always be the most informative and accurate measures of HRQOL in brain tumor patients. Supplementary or alternative measures, such as proxy-rated HRQOL measures and measures of instrumental activities of daily living, may provide a more complete picture of brain tumor patients' functioning in daily life.

Entities:  

Mesh：

Year:  2013        PMID： 23666388     DOI： 10.1007/s11910-013-0359-y

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN： 1528-4042            Impact factor:   5.081


  90 in total

Review 1.  Assessing meaningful change in quality of life over time: a users' guide for clinicians.

Authors:  Mirjam A G Sprangers; Carol M Moinpour; Timothy J Moynihan; Donald L Patrick; Dennis A Revicki
Journal:  Mayo Clin Proc       Date:  2002-06       Impact factor: 7.616

2.  The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires.

Authors:  D Osoba; N K Aaronson; M Muller; K Sneeuw; M A Hsu; W K Yung; M Brada; E Newlands
Journal:  Qual Life Res       Date:  1996-02       Impact factor: 4.147

Review 3.  Quality of life: what is it? How should it be measured?

Authors:  N K Aaronson
Journal:  Oncology (Williston Park)       Date:  1988-05       Impact factor: 2.990

4.  Improved, personalized treatment of glioma necessitates long-term follow-up of cognitive functioning.

Authors:  Jaap C Reijneveld; Martin Klein; Martin Jb Taphoorn; Tjeerd J Postma; Jan J Heimans
Journal:  Pharmacogenomics       Date:  2012-11       Impact factor: 2.533

5.  Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.

Authors:  Jaime Gállego Pérez-Larraya; François Ducray; Olivier Chinot; Isabelle Catry-Thomas; Luc Taillandier; Jean-Sébastien Guillamo; Chantal Campello; Annick Monjour; Stéphanie Cartalat-Carel; Maryline Barrie; Aymeri Huchet; Patrick Beauchesne; Mona Matta; Karima Mokhtari; Marie-Laure Tanguy; Jérôme Honnorat; Jean-Yves Delattre
Journal:  J Clin Oncol       Date:  2011-06-27       Impact factor: 44.544

6.  NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.

Authors:  Roger Stupp; Eric T Wong; Andrew A Kanner; David Steinberg; Herbert Engelhard; Volkmar Heidecke; Eilon D Kirson; Sophie Taillibert; Frank Liebermann; Vladimir Dbalý; Zvi Ram; J Lee Villano; Nikolai Rainov; Uri Weinberg; David Schiff; Lara Kunschner; Jeffrey Raizer; Jerome Honnorat; Andrew Sloan; Mark Malkin; Joseph C Landolfi; Franz Payer; Maximilian Mehdorn; Robert J Weil; Susan C Pannullo; Manfred Westphal; Martin Smrcka; Lawrence Chin; Herwig Kostron; Silvia Hofer; Jeffrey Bruce; Rees Cosgrove; Nina Paleologous; Yoram Palti; Philip H Gutin
Journal:  Eur J Cancer       Date:  2012-05-18       Impact factor: 9.162

7.  Perception of quality of life by patients, partners and treating physicians.

Authors:  K A Wilson; A J Dowling; M Abdolell; I F Tannock
Journal:  Qual Life Res       Date:  2000       Impact factor: 4.147

Review 8.  Health related quality of life assessment methodology and reported outcomes in randomised controlled trials of primary brain cancer patients.

Authors:  F Efficace; A Bottomley
Journal:  Eur J Cancer       Date:  2002-09       Impact factor: 9.162

Review 9.  Methodological issues in assessing health-related quality of life of colorectal cancer patients in randomised controlled trials.

Authors:  F Efficace; A Bottomley; V Vanvoorden; J M Blazeby
Journal:  Eur J Cancer       Date:  2004-01       Impact factor: 9.162

Review 10.  Health-related quality of life in non-small-cell lung cancer: methodologic issues in randomized controlled trials.

Authors:  Andrew Bottomley; Fabio Efficace; Ronald Thomas; Veerle Vanvoorden; Sam H Ahmedzai
Journal:  J Clin Oncol       Date:  2003-08-01       Impact factor: 44.544
View more
  10 in total

Review 1.  Patient reported endpoints for measuring clinical benefit in (high grade glioma) primary brain tumor patients.

Authors:  Terri S Armstrong; Mark R Gilbert
Journal:  Curr Treat Options Oncol       Date:  2014-12

2.  Subjective executive dysfunction in patients with primary brain tumors and their informants: relationships with neurocognitive, psychological, and daily functioning.

Authors:  Sarah Ellen Braun; Autumn Lanoye; Farah J Aslanzadeh; Ashlee R Loughan
Journal:  Brain Inj       Date:  2021-12-07       Impact factor: 2.311

Review 3.  Health-related quality of life in high-grade glioma patients.

Authors:  Linda Dirven; Neil K Aaronson; Jan J Heimans; Martin J B Taphoorn
Journal:  Chin J Cancer       Date:  2014-01

4.  Development of a questionnaire measuring instrumental activities of daily living (IADL) in patients with brain tumors: a pilot study.

Authors:  Q Oort; L Dirven; W Meijer; S A M Sikkes; B M J Uitdehaag; J C Reijneveld; M J B Taphoorn
Journal:  J Neurooncol       Date:  2017-02-01       Impact factor: 4.130

5.  Internet-based guided self-help for glioma patients with depressive symptoms: a randomized controlled trial.

Authors:  Florien W Boele; Martin Klein; Irma M Verdonck-de Leeuw; Pim Cuijpers; Jan J Heimans; Tom J Snijders; Maaike Vos; Ingeborg Bosma; Cees C Tijssen; Jaap C Reijneveld
Journal:  J Neurooncol       Date:  2017-12-13       Impact factor: 4.130

6.  The Effect of Pet Therapy and Artist Interactions on Quality of Life in Brain Tumor Patients: A Cross-Section of Art and Medicine in Dialog.

Authors:  Stefan Petranek; Jennifer Pencek; Mahua Dey
Journal:  Behav Sci (Basel)       Date:  2018-04-27

7.  Moving from clinician-defined to patient-reported outcome measures for survivors of high-grade glioma.

Authors:  Lena Rosenlund; Eskil Degsell; Asgeir Store Jakola
Journal:  Patient Relat Outcome Meas       Date:  2019-08-23

8.  Neurocognitive impairment and patient-proxy agreement on health-related quality of life evaluations in recurrent high-grade glioma patients.

Authors:  Ivan Caramanna; Martin Klein; Martin van den Bent; Ahmed Idbaih; Wolfgang Wick; Martin J B Taphoorn; Linda Dirven; Andrew Bottomley; Jaap C Reijneveld
Journal:  Qual Life Res       Date:  2022-08-18       Impact factor: 3.440

9.  Quality improvement of neuro-oncology services: integrating the routine collection of patient-reported, health-related quality-of-life measures.

Authors:  Rocío Fernández-Méndez; Rebecca J Rastall; William A Sage; Ingela Oberg; Gemma Bullen; Amy Louise Charge; Anna Crofton; Thomas Santarius; Colin Watts; Stephen J Price; Andrew Brodbelt; Alexis J Joannides
Journal:  Neurooncol Pract       Date:  2018-10-17

Review 10.  The use and impact of quality of life assessment tools in clinical care settings for cancer patients, with a particular emphasis on brain cancer: insights from a systematic review and stakeholder consultations.

Authors:  Sarah King; Josephine Exley; Sarah Parks; Sarah Ball; Teresa Bienkowska-Gibbs; Calum MacLure; Emma Harte; Katherine Stewart; Jody Larkin; Andrew Bottomley; Sonja Marjanovic
Journal:  Qual Life Res       Date:  2016-04-02       Impact factor: 4.147
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.